{"id":"W2898437318","doi":"10.1093/ofid/ofy210.552","title":"544. Pharmacokinetic Profile of Ibalizumab From a Phase 3 Trial","year":2018,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Theratechnologies (Canada)","funders":"","keywords":"Medicine; Pharmacokinetics; Tolerability; Dosing; Regimen; Viral load; Flow cytometry; Gastroenterology; Pharmacology; Internal medicine; Adverse effect; Human immunodeficiency virus (HIV); Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009081751,0.0006217335,0.001140837,0.0003004877,0.0003633638,0.001042639,0.0004018143,0.0007627779,0.003888562],"category_scores_gemma":[0.001017013,0.0003444747,0.0007122559,0.0002872556,0.0002394575,0.000375682,0.0001354548,0.001715055,0.001243386],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006560538,"about_ca_system_score_gemma":0.0008161184,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007536835,"about_ca_topic_score_gemma":0.001157479,"domain_scores_codex":[0.9996754,0.0001356517,0.00002058941,0.00004906654,0.00005123181,0.00006804007],"domain_scores_gemma":[0.9996952,0.00006161351,0.00006514532,0.00002758945,0.00003853098,0.0001119361],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5088201,0.01665293,0.009406459,0.0008504427,0.001797376,0.0006264525,0.0003051508,0.00360687,0.161598,0.0006119787,0.01964302,0.2760812],"study_design_scores_gemma":[0.4908504,0.369076,0.05891642,0.0002589288,0.001733905,0.001788769,0.00008472086,0.007014466,0.02630695,0.00104249,0.04279128,0.0001357601],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9737846,0.007119975,0.002018626,0.001044765,0.000217568,0.003048937,0.003902429,0.0003351494,0.008527836],"genre_scores_gemma":[0.9776155,0.002300854,0.00224995,0.001996995,0.000189812,0.00330344,0.006088238,0.0001195638,0.006135672],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003888562,"threshold_uncertainty_score":0.01300848,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03233963132046469,"score_gpt":0.3997946681614323,"score_spread":0.3674550368409676,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}